Direct thrombin inhibitors: current status and future prospects.
暂无分享,去创建一个
[1] M. Simoons. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.
[2] T. Verbeuren,et al. S 18326: a thrombin inhibitor that shows potential for oral treatment of thromboembolic disorders. , 1999, Expert opinion on investigational drugs.
[3] R. Collins,et al. Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) , 1997 .
[4] J W Fenton,et al. Regulation of Thrombin Generation and Functions , 1988, Seminars in thrombosis and hemostasis.
[5] M. Verstraete. Direct Thrombin Inhibitors: Appraisal of the Antithrombotic/ Hemorrhagic Balance , 1997, Thrombosis and Haemostasis.
[6] H. Büller,et al. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group. , 1993, Journal of the American College of Cardiology.
[7] B. Lämmle,et al. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors. , 1985, Clinics in haematology.
[8] P. Serruys,et al. Clinical Trials of Direct Thrombin Inhibitors During Invasive Procedures , 1997, Thrombosis and Haemostasis.
[9] U. Tebbe,et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) , 1994, Circulation.
[10] J. Maraganore,et al. Thrombin structure and function: why thrombin is the primary target for antithrombotics. , 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[11] A. Gast,et al. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[12] V. Wheaton,et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.
[13] J. Hirsh,et al. Advances in Antithrombotic Therapy: Novel Agents , 1995, Thrombosis and Haemostasis.
[14] M. Ghorab,et al. Improvement of the biological performance of oral anticoagulant drugs. 2. Dicumarol. , 1997, Die Pharmazie.
[15] P. Serruys,et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. , 1995, The New England journal of medicine.
[16] P. Wille-Jørgensen,et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. , 1997, The New England journal of medicine.
[17] F. Markwardt. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent in medicinal leeches. , 1985, Biomedica biochimica acta.
[18] B. Lucchesi,et al. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. , 1997, Journal of cardiovascular pharmacology.
[19] Y. Hijikata,et al. THROMBIN INHIBITORS. 3. CARBOXYL-CONTAINING AMIDE DERIVATIVES OF Nα-SUBSTITUTED L-ARGININE , 1981 .
[20] P. Tracy. Regulation of Thrombin Generation at Cell Surfaces , 1988, Seminars in thrombosis and hemostasis.
[21] L. Wilkins. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. , 1994, Circulation.
[22] M. Talbot. Recombinant hirudin: a new prospect in thrombosis. , 1991, Current studies in hematology and blood transfusion.
[23] K. Menear,et al. Progress towards the discovery of orally active thrombin inhibitors. , 1998, Current medicinal chemistry.
[24] V. Fuster,et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. , 1998, Journal of the American College of Cardiology.
[25] T. Urano,et al. The physiological aspects of fibrinolysis. , 1994, Thrombosis research.
[26] J. Vacca,et al. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis. , 1999, The Journal of pharmacology and experimental therapeutics.
[27] P. Held,et al. 931-115 Phase I Studies on Inogatran, a New Selective Thrombin Inhibitor , 1995 .
[28] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[29] F. Markwardt,et al. Pharmacological survey of recombinant hirudin. , 1988, Die Pharmazie.
[30] J. Fareed,et al. Synthetic and recombinant antithrombin drugs. , 1998, Expert opinion on investigational drugs.
[31] T. Tezuka,et al. Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of N alpha-substituted L-arginine. , 1980, Journal of medicinal chemistry.
[32] R. W. Harper,et al. Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacy. , 1999, Bioorganic & medicinal chemistry letters.
[33] H. Ehringer,et al. An Exploratory Trial of Two Dosages of a Novel Synthetic Thrombin Inhibitor (Napsagatran, Ro 46-6240) Compared with Unfractionated Heparin for Treatment of Proximal Deep-vein Thrombosis , 1997, Thrombosis and Haemostasis.
[34] J. Pogue,et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. , 1998, Circulation.
[35] J. Vacca,et al. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates. , 1998, Journal of medicinal chemistry.
[36] U. Tebbe,et al. Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis). , 1995, European heart journal.
[37] U. Janssens,et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. , 1999, Circulation.